Levemir Innolet (Insulin Detemir)

Insulin detemir binds to insulin receptors on muscle, fat and liver cells, activating intracellular pathways that increase glucose uptake and suppress hepatic glucose production. Its fatty‑acid side chain prolongs binding to albumin, giving a flat, 24‑hour insulin profile.

The dose of Levemir Innolet is individualized. A qualified prescriber determines the appropriate amount based on the patient’s age, weight, type of diabetes, current glycaemic control, and other medications. No fixed regimen is provided here.

Data on insulin detemir use during pregnancy and lactation are limited. It may be used if the potential benefit outweighs any risk to the fetus or infant. Treatment decisions should be made by a healthcare professional familiar with the patient’s condition.

To order Levemir Innolet, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, cold‑chain shipping details and necessary import documentation.

Levemir Innolet (insulin detemir) offers a relatively flat 24‑hour profile and lower intra‑patient variability compared with some older basal insulins. Compared with insulin glargine, detemir has a shorter duration in some patients, which may require twice‑daily dosing, but it is less likely to cause weight gain.

Levemir Innolet must be stored in a refrigerator at 2‑8 °C. Keep the vial in its original carton, protect it from light, and avoid freezing. Once in use, the solution can be kept at controlled room temperature (up to 30 °C) for a maximum of 28 days, as indicated on the label.

Levemir Innolet is given by subcutaneous injection, typically into the abdomen, thigh or upper arm. It should be injected into a different site each day to reduce lipodystrophy risk. The injection technique follows standard insulin administration guidelines, and patients should rotate sites systematically.

The most serious risks include severe hypoglycaemia, which can cause loss of consciousness or seizures, and allergic reactions such as anaphylaxis. Patients should be educated to recognise early signs of low blood glucose and to seek immediate medical help if a severe allergic response occurs.

Levemir Innolet is contraindicated in individuals with a known hypersensitivity to insulin detemir or any of the excipients in the formulation. It should also be avoided in patients with severe hypoglycaemia unawareness unless closely supervised by a healthcare professional.